# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from ...
Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late...
JMP Securities analyst Reni J. Benjamin reiterates Summit Therapeutics (NASDAQ:SMMT) with a Market Outperform and maintains ...
Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.
Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This...
Summit Plans to Submit a BLA in Q4 2025 for Ivonescimab Based on HARMONi Global Phase III Study ResultsExpansion of Summit'...
Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti...